The therapeutic efficacy of Metformin can be decreased when used in combination with Asenapine. The therapeutic efficacy of Metformin can be decreased when used in combination with Dexamethasone. Metformin may increase the hypoglycemic activities of Sulfamethoxazole. The serum concentration of Metformin can be increased when it is combined with Glycopyrronium. The therapeutic efficacy of Metformin can be decreased when used in combination with Fosamprenavir. Escitalopram may increase the hypoglycemic activities of Metformin. Methyltestosterone may increase the hypoglycemic activities of Metformin. The risk or severity of adverse effects can be increased when Ioversol is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Pasireotide. The therapeutic efficacy of Metformin can be decreased when used in combination with Paliperidone. The therapeutic efficacy of Metformin can be decreased when used in combination with Diazoxide. Metformin may increase the hypoglycemic activities of Insulin Lispro. Nalidixic Acid may increase the hypoglycemic activities of Metformin. The risk or severity of adverse effects can be increased when Iodixanol is combined with Metformin. Trans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Metformin. Aloxiprin may increase the hypoglycemic activities of Metformin. The serum concentration of Metformin can be increased when it is combined with Cimetidine. The therapeutic efficacy of Metformin can be decreased when used in combination with Estrone sulfate. The therapeutic efficacy of Metformin can be decreased when used in combination with Lurasidone. The therapeutic efficacy of Metformin can be decreased when used in combination with Octreotide. The therapeutic efficacy of Metformin can be increased when used in combination with Ubidecarenone. The therapeutic efficacy of Metformin can be decreased when used in combination with Ethinyl Estradiol. The therapeutic efficacy of Metformin can be decreased when used in combination with Furosemide. The therapeutic efficacy of Metformin can be decreased when used in combination with Dabrafenib. The therapeutic efficacy of Metformin can be decreased when used in combination with Triamcinolone. The therapeutic efficacy of Metformin can be decreased when used in combination with Prednisone. The therapeutic efficacy of Metformin can be decreased when used in combination with Buserelin. Nandrolone decanoate may increase the hypoglycemic activities of Metformin. Mesterolone may increase the hypoglycemic activities of Metformin. Mebanazine may increase the hypoglycemic activities of Metformin. Mesalazine may increase the hypoglycemic activities of Metformin. The risk or severity of adverse effects can be increased when Methazolamide is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Betamethasone. The therapeutic efficacy of Metformin can be decreased when used in combination with Desogestrel. Temafloxacin may increase the hypoglycemic activities of Metformin. Indalpine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Drospirenone. Metformin may increase the hypoglycemic activities of Sulfadiazine. The serum concentration of Trospium can be decreased when it is combined with Metformin. The risk or severity of adverse effects can be increased when Ioxilan is combined with Metformin. Phenelzine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Tacrolimus. Hydracarbazine may increase the hypoglycemic activities of Metformin. The risk or severity of adverse effects can be increased when Ethoxzolamide is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Bendroflumethiazide. The risk or severity of adverse effects can be increased when Acetazolamide is combined with Metformin. Metformin may increase the hypoglycemic activities of Tolbutamide. The therapeutic efficacy of Metformin can be decreased when used in combination with Prednisolone. The therapeutic efficacy of Metformin can be decreased when used in combination with Danazol. Metformin may increase the hypoglycemic activities of Glimepiride. The therapeutic efficacy of Metformin can be decreased when used in combination with Trichlormethiazide. The therapeutic efficacy of Metformin can be decreased when used in combination with Darunavir. Stanozolol may increase the hypoglycemic activities of Metformin. Levomilnacipran may increase the hypoglycemic activities of Metformin. Nandrolone may increase the hypoglycemic activities of Metformin. Citalopram may increase the hypoglycemic activities of Metformin. Prulifloxacin may increase the hypoglycemic activities of Metformin. The risk or severity of adverse effects can be increased when Brinzolamide is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Cyclopenthiazide. Metformin may increase the hypoglycemic activities of Nateglinide. Cinoxacin may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Lanreotide. The therapeutic efficacy of Metformin can be decreased when used in combination with Indapamide. Metformin may increase the hypoglycemic activities of Insulin Aspart. The therapeutic efficacy of Metformin can be decreased when used in combination with Everolimus. The therapeutic efficacy of Metformin can be decreased when used in combination with Medroxyprogesterone acetate. GLPG-0492 may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Megestrol acetate. The therapeutic efficacy of Metformin can be decreased when used in combination with Epinephrine. The therapeutic efficacy of Metformin can be decreased when used in combination with Tipranavir. Grepafloxacin may increase the hypoglycemic activities of Metformin. Alaproclate may increase the hypoglycemic activities of Metformin. Paroxetine may increase the hypoglycemic activities of Metformin. Iproniazid may increase the hypoglycemic activities of Metformin. Acetylsalicylic acid may increase the hypoglycemic activities of Metformin. Metformin may increase the hypoglycemic activities of Insulin Glulisine. The therapeutic efficacy of Metformin can be decreased when used in combination with Nelfinavir. The risk or severity of adverse effects can be increased when Diclofenamide is combined with Metformin. Levofloxacin may increase the hypoglycemic activities of Metformin. Etoperidone may increase the hypoglycemic activities of Metformin. Moclobemide may increase the hypoglycemic activities of Metformin. Nitroaspirin may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Chlorothiazide. The therapeutic efficacy of Metformin can be decreased when used in combination with Dienogest. The therapeutic efficacy of Metformin can be decreased when used in combination with Saquinavir. Lipoic Acid may increase the hypoglycemic activities of Metformin. Testosterone may increase the hypoglycemic activities of Metformin. Metformin may increase the hypoglycemic activities of Tolazamide. The therapeutic efficacy of Metformin can be decreased when used in combination with Cortisone acetate. The therapeutic efficacy of Metformin can be decreased when used in combination with Sirolimus. Metformin may increase the hypoglycemic activities of Glyburide. The therapeutic efficacy of Metformin can be decreased when used in combination with Methylprednisolone. The therapeutic efficacy of Metformin can be decreased when used in combination with Fludrocortisone. The risk or severity of adverse effects can be increased when Diatrizoate is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Triptorelin. The therapeutic efficacy of Metformin can be decreased when used in combination with Methyclothiazide. The therapeutic efficacy of Metformin can be decreased when used in combination with Ceritinib. The therapeutic efficacy of Metformin can be decreased when used in combination with Norethisterone. Sertraline may increase the hypoglycemic activities of Metformin. The risk or severity of adverse effects can be increased when Ethiodized oil is combined with Metformin. Flumequine may increase the hypoglycemic activities of Metformin. 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Metolazone. Tranylcypromine may increase the hypoglycemic activities of Metformin. The serum concentration of Dalfampridine can be increased when it is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Quinethazone. The therapeutic efficacy of Metformin can be decreased when used in combination with Methotrimeprazine. The therapeutic efficacy of Metformin can be decreased when used in combination with Etacrynic acid. The therapeutic efficacy of Metformin can be decreased when used in combination with Cyproterone acetate. The therapeutic efficacy of Metformin can be decreased when used in combination with Pipotiazine. Caroxazone may increase the hypoglycemic activities of Metformin. Dapoxetine may increase the hypoglycemic activities of Metformin. Safrazine may increase the hypoglycemic activities of Metformin. The risk or severity of adverse effects can be increased when Ethanol is combined with Metformin. Metformin may increase the hypoglycemic activities of Sulfisoxazole. The therapeutic efficacy of Metformin can be decreased when used in combination with Temsirolimus. The therapeutic efficacy of Metformin can be decreased when used in combination with Ethynodiol diacetate. The therapeutic efficacy of Metformin can be decreased when used in combination with Corticotropin. Testosterone Propionate may increase the hypoglycemic activities of Metformin. The risk or severity of adverse effects can be increased when Dorzolamide is combined with Metformin. Furazolidone may increase the hypoglycemic activities of Metformin. Iproclozide may increase the hypoglycemic activities of Metformin. Gemifloxacin may increase the hypoglycemic activities of Metformin. Metformin may increase the hypoglycemic activities of Sunitinib. Trolamine salicylate may increase the hypoglycemic activities of Metformin. Venlafaxine may increase the hypoglycemic activities of Metformin. The risk or severity of adverse effects can be increased when Topiramate is combined with Metformin. Pazufloxacin may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Piperazine. Desvenlafaxine may increase the hypoglycemic activities of Metformin.